CRNX Stock Crinetics Pharmaceuticals (CRNX, $54.63) Stochastic Oscillator left the oversold zone on December 16, 2024

GET DAILY SIGNALS

Get AI intraday signals

CRNX - Crinetics Pharmaceuticals

Stochastic signal

View

Odds of UP Trend

Price: $54.63

Daily change: +$0.97 (+1.81%)

Daily volume: 1.2M

Capitalization: $5.1B

Industry: Biotechnology

CRNX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on December 13, 2024

CRNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where CRNX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNX advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 166 cases where CRNX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRNX moved out of overbought territory on November 11, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on CRNX as a result. In of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRNX turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at .

CRNX moved below its 50-day moving average on December 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CRNX crossed bearishly below the 50-day moving average on December 17, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CRNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.165) is normal, around the industry mean (14.678). P/E Ratio (0.000) is within average values for comparable stocks, (87.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). CRNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). CRNX's P/S Ratio (3333.333) is very high in comparison to the industry average of (260.407).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.